Innovent's NDA for PD-1 drug as first-line treatment for ESCC accepted in China
Elise Mak ·29 days ago
News


Innovent Biologics said China's NMPA has accepted the supplemental NDA for its PD-1 drug sintilimab in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as the first-line treatment of esophageal squamous cell carcinoma (ESCC).

The supplemental NDA application is based on the interim analysis of the global randomized, double-blind, multi-center phase 3 ORIENT-15 clinical trial – which evaluated sintilimab in combination with chemotherapy compared to placebo in combination with chemotherapy as first-line therapy for ESCC.

Based on the interim analysis conducted by the independent data monitoring committee, sintilimab in combination with chemotherapy demonstrated a statistically significant improvement in the primary endpoint of overall survival compared to placebo in combination with chemotherapy, regardless of PD-L1 expression status. The results of ORIENT-15 were presented at ESMO on September 17.

The results of ORIENT-15 demonstrated that sintilimab plus chemotherapy significantly improved overall survival and progression-free survival compared to chemotherapy. These results suggest that this sintilimab regimen could be a suitable treatment option for ESCC patients in China, said Shen Lin, principal investigator of the ORIENT-15 study.

In China, sintilimab has been approved for four indications, including relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous non-small cell lung cancer (NSCLC), in combination with gemcitabine and platinum chemotherapy for the first-line treatment of squamous NSCLC, and in combination with bevacizumab biosimilar for the first-line treatment of hepatocellular carcinoma.


Keywords: Innovent ESCC NDA NMPA
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement